<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926068</url>
  </required_header>
  <id_info>
    <org_study_id>HO-09-01</org_study_id>
    <nct_id>NCT00926068</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers</brief_title>
  <acronym>Truheal</acronym>
  <official_title>Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealOr</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinigene International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealOr</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double blind, randomized, placebo controlled, outpatient, parallel group
      comparison trial to assess the safety and efficacy of HO/03/03 10µg versus Placebo, applied
      topically once daily for up to 14 weeks in at least 196 subjects diagnosed with Diabetes
      Mellitus and having a single target non-healing Plantar Neuropathic Diabetic Foot Ulcer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete ulcer closure</measure>
    <time_frame>Up to 14 weeks inclusive</time_frame>
    <description>Time to Event Analysis that determines time for incidence of 100% study wound closure per unit of time (days) and the incidence of 100% wound closure per unit of time using the log rank test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in wound area at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>75% wound closure by or on Study Week 14</measure>
    <time_frame>Up to 14 weeks inclusive</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, changes in vital signs, physical examination, electrocardiogram and laboratory tests from baseline to termination.</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of 100% Closure tested by the Fisher exact 2-tailed test</measure>
    <time_frame>Up to 14 weeks inclusive</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in granulation tissue at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of improved ulcers</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>HO/03/03 10µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HO/03/03 10µg</intervention_name>
    <arm_group_label>HO/03/03 10µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 80 years, extremes included

          2. Diagnosed with Diabetes Mellitus Type 1 or Type 2

          3. Having a documented single target non-healing Plantar Neuropathic Diabetic Foot Ulcer
             with a minimal duration of 4 weeks prior to the informed consent signature

          4. Ulcer size at randomization:

               -  Wagner grade 1, between 2.0 cm2 to 10 cm2, extremes included or;

               -  Wagner grade 2, between 1.0 cm2 to 10 cm2, extremes included;

          5. Single target, ulcer on the study foot:

               -  Wagner grade 1 or;

               -  Wagner grade 2 (does not involve abscess or osteomyelitis);

          6. Target ulcer area decreased by ≤ 30% OR ≤ 0.1 cm/wk edge healing rate measured after
             debridement at screening to after debridement if clinically indicated at
             randomization.

          7. Glycosylated Haemoglobin A1c (HbA1c) ≤ 12%;

          8. Ankle to Brachial Index (ABI) on study foot:

               -  0.7 ≤ ABI ≤ 1.2 or

               -  ABI &gt; 1.2 and toe pressure &gt; 50 mm Hg (ABI measured by Doppler; toe blood
                  pressure measured by toe cuff);

          9. Diabetic Neuropathy is confirmed by neurological testing

         10. Subject should be available for the entire study period, and be able and willing to
             adhere to protocol requirements

         11. Subject has signed the informed consent form prior to any study protocol related
             procedure

        Exclusion Criteria:

        Subjects meeting one or more of the following criteria cannot be selected:

          1. Anamnesis of current or recent past (within the last 2 years) abuse of alcohol,
             barbiturates, benzodiazepines, amphetamines, narcotics, cocaine, psychoactive drugs or
             other abused substances that will interfere with treatment compliance

          2. Use of growth factors, skin graft or participation in an investigational study within
             the last 30 days prior to the beginning of the screening period

          3. Females who are pregnant, lactating, of child-bearing potential, or post-menopausal
             for less than 2 years and not using a medically approved method of contraception or
             females who test positive on a blood-based pregnancy test

          4. Have a documented medical history of HIV, HBV or HCV

          5. Have a documented medical history of a significant cardiac, pulmonary,
             gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), metabolic,
             neurological, hepatic or nephrologic disease and/or receiving dialysis

          6. Anaemia (Haemoglobin &lt; 9 gram/dL for females or Haemoglobin &lt; 10 gram/dL for males) or
             White Blood Cells count &gt; 11,000/μL or Platelets count &lt; 100,000/μL or impaired renal
             function (Creatinine &gt; 3 mg/dL) or liver function tests &gt; 3 times upper normal lab
             values or any indication of malnourishment (Albumin &lt; 2.8 g/dL) or any other
             clinically significant biochemistry, haematology and urinalysis tests;

          7. Had any clinically significant illness during the last 4 weeks prior to the screening
             period;

          8. Have a current malignancy or a past malignancy in the last 5 years other than Basal
             Cell Carcinoma or is treated by radio/chemotherapy

          9. Have any signs of clinical infection in the wound (which could be linked to raised
             body temperature, abscess, osteomyelitis, necrosis or erythema)

         10. Had any antibiotic treatment during the screening period;

         11. Had evidence of infection or osteomyelitis on a plain foot x-ray at screening;

         12. Is bed-ridden or unable to come to the clinic;

         13. Have more than one target non-healing Diabetic Foot Ulcer per subject;

         14. Plantar Neuropathic DFU is located on an active Charcot foot;

         15. Have hind foot ulcer or have a foot deformity/condition preventing the use of offload
             footwear;

         16. Had a leg revascularization surgery within the last 6 months or be a candidate for
             revascularization surgery during the course of the study;

         17. Glucocorticosteroid treatment (Prednisone &gt;10 mg/day or its equivalent)

         18. Inability to stop alternative wound healing treatment (e.g. Becaplermin or other
             topical products) following debridement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phoenix VA Healthcare System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Clinical Research</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ian Gordon</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Technologies, LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California School of Podiatric Medicine at Samuel Merritt University</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North American Centre for Limb Preservation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System-Wound Clinic Bay Pines VA Healthcare System-Research Pharmacy</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Network</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capt. James A. Lovell Federal Health Care Center</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic Downtown-Research Institute</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Wound Care Center IDI Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Curative &amp; Palliative Wound Care Calvary Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Armstrong County Memorial Hospital Snyder Institute for Vascular Health and Research</name>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddington Testing Company</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete Family Foot Care</name>
      <address>
        <city>Mc Allen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medanta</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jain Institute of Vascular Sciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karnataka Institute of Diabetology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560069</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.John's Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>580034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgaum Diabetes Centre</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>59001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinaya Hospital and Research Centre</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunnamkulam Eye and Diabetes Centre</name>
      <address>
        <city>Thrissur</city>
        <state>Kerala</state>
        <zip>680 503</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OM Shree Swami Samarth Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patil Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MV Hospital for Diabetes Pvt Ltd</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. V Seshiah Diabetes Research Institute</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamilnadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SK Diabetes Research &amp; Education Center</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medicare &amp; Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2009</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Foot Ulcer</keyword>
  <keyword>DFU</keyword>
  <keyword>Wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

